What immune effects does Polivy (polatuzumab vedotin) have?
Polivy is an antibody-drug conjugate that targets CD79b on B cells. After it binds to B cells, it delivers a chemotherapy payload that kills those cells. As a result, Polivy can reduce certain parts of the patient’s immune system by lowering or disrupting B-cell function and the B-cell populations that help make antibodies.
This matters clinically because B-cell depletion can increase vulnerability to infections, especially in patients who also receive other immune-suppressing cancer therapies (common in lymphoma regimens).
How does Polivy change infection risk?
By attacking CD79b-positive B cells, Polivy can contribute to immune suppression that shows up in practice as higher rates of infections in treated patients. In real-world use, infection risk is also influenced by the rest of the regimen (Polivy is often given with rituximab and chemotherapy) and by the patient’s baseline status, such as prior treatment and blood counts.
Patients are typically monitored for signs of infection and low white blood cells during treatment. If you’re asking because of symptoms (fever, cough, burning with urination, or sudden worsening fatigue), those should be treated as urgent while on therapy.
Does Polivy affect T cells or overall immunity?
Polivy’s primary direct target is CD79b on B cells rather than T cells. Still, immune effects can be broader indirectly:
- Reduced B-cell activity can lower antibody-mediated defense against germs.
- Treatment combinations and chemotherapy can also suppress bone marrow function, which reduces white blood cells that fight infection.
So even if Polivy is B-cell–directed, the overall immune impact depends on the full treatment plan.
What’s different about Polivy versus plain chemo or rituximab?
Compared with conventional chemotherapy, Polivy is designed to deliver its cytotoxic payload specifically to CD79b-expressing cells. That targeting can change the immune profile versus non-specific cytotoxic drugs.
At the same time, many Polivy regimens include other agents (for example, rituximab), which also suppress B-cell function. So the combined regimen can deepen or prolong immune suppression beyond Polivy alone.
What should patients monitor for while on Polivy?
People receiving Polivy are generally monitored for infection-related issues and for blood-count changes (especially neutropenia or other low white blood cell states) during treatment cycles. Patients should contact their care team promptly for fever or signs of infection, and they should follow any guidance on vaccines and infection precautions provided by their oncology team.
If you tell me the exact regimen (for example, Polivy with rituximab plus which chemotherapy) and whether you’re asking about a specific side effect you’re experiencing, I can narrow the explanation to the most likely immune-related mechanism in that context.